Skip to main content
. Author manuscript; available in PMC: 2024 Nov 15.
Published in final edited form as: Semin Liver Dis. 2022 Aug 31;42(4):423–433. doi: 10.1055/a-1934-5588

Fig. 2.

Fig. 2

Free fatty acid (FFA) loading for nonalcoholic fatty liver disease (NAFLD) organoid model. (A) Progression of disease at the organ level with contributing factors. (B) Depiction of how treating liver organoids with FFA with or without costimulation with lipopolysaccharide (LPS) or TGF-beta can model the NAFLD disease process at the individual cell level with NAFLD phenotypes in fibrosis, angiogenesis, and inflammation. NASH, nonalcoholic steatohepatitis.